Cencora Inc. (COR)

Sep 25, 2026

This article compares AbbVie and Pfizer, two pharmaceutical giants, for investors looking at 2026. AbbVie is transitioning its focus to newer immunology drugs, while Pfizer is pursuing aggressive acquisitions in oncology and metabolic assets to counter post-pandemic revenue declines and upcoming patent expirations. While both offer significant dividends, Pfizer appears to be the more undervalued stock based on current valuation metrics, despite AbbVie's promising pipeline.

Sep 25, 2026

This article compares AbbVie and Pfizer, two pharmaceutical giants, for investors in 2026, analyzing their financial performance, product pipelines, and risk profiles. While AbbVie is transitioning from its Humira era with new immunology leaders, Pfizer is focusing on oncology and metabolic assets through acquisitions, navigating post-pandemic changes and patent expirations. The author ultimately suggests Pfizer is currently undervalued despite AbbVie's promising pipeline, due to Pfizer's lower valuation metrics and recent growth in its oncology business.

Sep 19, 2026

Cencora (COR) reported strong fiscal third-quarter results, with revenue up 5.1% and adjusted EPS climbing 12.0%, leading to raised full-year guidance and $1 billion in stock repurchases. However, this profit growth significantly outpaced sales growth, driven by the OneOncology acquisition which also introduced higher operating expenses and debt. The article highlights a key tension: while profit margins improved due to the acquisition, the long-term sustainability is questioned by increased costs, interest expenses, and the rising volume of lower-margin GLP-1 drugs.

Sep 18, 2026

This article compares AbbVie (NYSE:ABBV) and Bristol Myers Squibb (NYSE:BMY) as potential healthcare stock investments for 2026, weighing their financial performance, growth strategies, and risk profiles. While Bristol Myers Squibb appears cheaper based on valuation metrics, AbbVie is recommended due to its successful navigation of patent cliffs and strong immunology and neuroscience pipeline, making it a more predictable choice for patient investors.

Sep 17, 2026

This article compares Amgen and Vertex Pharmaceuticals to determine which healthcare stock is a better investment in 2026. While Amgen offers stability and a diversified portfolio, Vertex Pharmaceuticals is highlighted for its high-growth potential, dominant position in cystic fibrosis, expanding pipeline, and superior operating margins. The author ultimately recommends Vertex for long-term investors seeking growth in the healthcare sector.